Latest Healthcare Software News

Enlitic has launched its cloud-based Ensight platform in the US through a phased deployment with Radiology Imaging Associates, generating an initial annual recurring revenue of approximately US$50,000 and setting the stage for broader expansion.

Global Health Limited boosted customer receipts by 12.6% to A$9.53 million for FY26, completing its SaaS platform upgrade and cutting cash burn by 30%. The company targets sustained EBITDA profitability and international expansion in FY27.

Echo IQ has locked in a binding Heads of Agreement with Pro Medicus for a strategic A$20 million investment and a US commercial partnership to accelerate adoption of its AI-powered cardiac diagnostic platform.

Alcidion has landed a $35 million, seven-year contract to deploy its Miya Precision Electronic Patient Record platform at University Hospitals Sussex, marking a significant expansion in the UK healthcare IT market.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

Alcidion Group Limited has reported a robust half-year performance with a 44% revenue increase and a return to profitability, driven by key contract expansions and new wins in the UK and Australia. The company is now positioned to secure a major Electronic Patient Record contract with University Hospitals Sussex NHS Foundation Trust.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.

Oneview Healthcare PLC reported a 21% increase in total revenue to €12 million for the year ended 31 December 2025, driven by growth in recurring revenue and customer expansion. Despite this, the company’s loss after tax widened to €12.6 million, reflecting ongoing investment and cost pressures.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.